Immunotherapy Trial Leaves Bowel Cancer Patients

How Does Immunotherapy Work for Mismatch Repair-Deficient Bowel Cancer?

Mismatch repair-deficient (dMMR) tumors carry an unusually high number of genetic mutations because the cellular machinery that normally corrects DNA replication errors is broken. This high mutational burden produces abnormal proteins on the cancer cell surface that the immune system can recognize as foreign — but tumors often evade detection by exploiting the PD-1/PD-L1 checkpoint pathway, which acts as a brake on T-cell activity.

Checkpoint inhibitors such as dostarlimab and pembrolizumab block this brake, allowing T-cells to mount a sustained attack on tumor cells. In dMMR cancers, which represent roughly 10–15% of colorectal cancers and a higher proportion of early-stage rectal cancers, this approach has produced response rates that researchers describe as unprecedented in solid tumor oncology. The trial findings extend earlier work by Dr. Andrea Cercek and Dr. Luis Diaz at Memorial Sloan Kettering, where every patient in an initial cohort achieved a complete clinical response.

What Does This Mean for Patients Avoiding Surgery and Chemotherapy?

Standard treatment for locally advanced rectal cancer typically involves a combination of chemotherapy, radiation, and major surgery — interventions that can cause permanent bowel and bladder dysfunction, sexual dysfunction, infertility, and the need for a permanent colostomy. For younger patients especially, these side effects represent a lifelong burden even after successful cancer control.

The emerging immunotherapy-only approach, often described as an "organ-sparing" or "watch-and-wait" strategy, could fundamentally change the treatment paradigm for the dMMR subgroup. Patients who achieve a complete clinical response after a course of checkpoint inhibitor therapy enter active surveillance rather than proceeding to surgery. The nearly three-year cancer-free interval reported in the latest follow-up provides important evidence that these responses are durable, not just transient. Researchers caution, however, that longer follow-up is needed and that universal tumor testing for mismatch repair status is essential to identify candidates.

Who Qualifies for This Treatment Approach?

Identifying eligible patients requires molecular testing of tumor tissue. Pathologists check for loss of mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) using immunohistochemistry, or test for microsatellite instability-high (MSI-H) status using PCR or next-generation sequencing. Major oncology guidelines from the National Comprehensive Cancer Network and the European Society for Medical Oncology now recommend universal mismatch repair testing for all newly diagnosed colorectal cancers.

Patients whose tumors are mismatch repair-proficient (the majority of colorectal cancers) do not respond as robustly to checkpoint inhibitors and still require conventional treatment. This underscores the importance of precision oncology — matching the right treatment to the right tumor biology — rather than applying a one-size-fits-all approach.